Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)

NCT06455280 is registered in ClinicalTrials.gov with Elizabeth C. Verna as lead sponsor.

NCT NCT06455280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06455280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)
Lead sponsor
Elizabeth C. Verna
Phase
Phase 1
Overall status
Recruiting
Start date
September 11, 2024
Completion date
March 31, 2028
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hepatitis, autoimmune liver disease, cirrhosis, liver, end stage liver disease, liver transplant disorder, primary sclerosing cholangitis